Trikafta/Kaftrio was the largest of Vertex Pharmaceuticals Inc / Ma’s 7 reported lines in fiscal 2025, at $10.31B — 85% of $12.10B.
| Product and Service | FY 2013 | FY 2015 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trikafta/Kaftrio | $7.69B | $8.94B | $10.24B | $10.31B | ||||||||||||||||||||
| Orkambi | — | — | — | — | ||||||||||||||||||||
| Other Product Revenues | $1.24B | $924.50M | $781.50M | $820.10M | ||||||||||||||||||||
| Product Revenues, Net | — | $30.20M | $35.70M | -$73.30M | ||||||||||||||||||||
| Kalydeco | — | — | — | — | ||||||||||||||||||||
| Alyftrek | — | — | — | $837.80M | ||||||||||||||||||||
| Symdeko/Symkevi | — | — | — | — | ||||||||||||||||||||
| Other | — | — | — | — | ||||||||||||||||||||
| Incivek | — | — | — | — | ||||||||||||||||||||
| Casgevy | — | — | $10.00M | $115.80M | ||||||||||||||||||||
| Journavx | — | — | — | $59.60M | ||||||||||||||||||||
| Other Revenues | — | — | — | $30.70M | ||||||||||||||||||||
| Collaborative & Royalty Revenues | — | — | — | — | ||||||||||||||||||||
| Total | $8.93B | $9.90B | $11.07B | $12.10B |
In fiscal 2025, which ended December 31, 2025, the 7 revenue lines Vertex Pharmaceuticals Inc / Ma reported in this breakdown added up to $12.10B. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $11.07B reported that year. Trikafta/Kaftrio was the largest revenue line, at $10.31B or 85.2% of the total, followed by Alyftrek ($837.80M, 6.9%) and Other Product Revenues ($820.10M, 6.8%). Together, the two largest revenue lines made up 92.1% of this total.
Compared with fiscal 2024, Other Product Revenues grew the fastest, rising 4.9% to $820.10M. Because revenue lines were added or dropped between the two years, part of this reflects how Vertex Pharmaceuticals Inc / Ma regrouped its reporting.
Alyftrek (fiscal 2025), Casgevy (fiscal 2024) and Journavx (fiscal 2025) were first reported as separate revenue lines during this period. Figures are shown as reported, so the total is net of Product Revenues, Net, which was -$73.30M in fiscal 2025. The table also keeps 6 revenue lines that Vertex Pharmaceuticals Inc / Ma no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers 24 fiscal years between 2013 and 2025, as reported in Vertex Pharmaceuticals Inc / Ma's annual filings.
United States was the largest of Vertex Pharmaceuticals Inc / Ma’s 3 reported lines in fiscal 2025, at $7.55B — 63% of $12.00B.
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $5.70B | $6.04B | $6.68B | $7.55B | ||||||||||||
| Revenues | — | — | — | — | ||||||||||||
| Europe | $2.71B | $3.11B | $3.45B | $3.46B | ||||||||||||
| Other | $525.90M | $719.80M | $881.30M | $992.40M | ||||||||||||
| Outside Of The United States | — | — | — | — | ||||||||||||
| Total | $8.93B | $9.87B | $11.02B | $12.00B |
In fiscal 2025, which ended December 31, 2025, the 3 regions Vertex Pharmaceuticals Inc / Ma reported in this breakdown added up to $12.00B. That was up 8.9% from $11.02B in fiscal 2024. United States was the largest region, at $7.55B or 62.9% of the total, followed by Europe ($3.46B, 28.8%) and Other ($992.40M, 8.3%). Together, the two largest regions made up 91.7% of this total.
Compared with fiscal 2024, United States grew the fastest, rising 12.9% to $7.55B. Every sizeable region reported in both years grew. Over fiscal 2022 to 2025, revenue across these regions went from $8.93B to $12.00B, a compound annual growth rate of 10.4%. United States' share of the total fell from 63.8% to 62.9% over the same years.
The table also keeps 2 regions that Vertex Pharmaceuticals Inc / Ma no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers 16 fiscal years between 2009 and 2025, as reported in Vertex Pharmaceuticals Inc / Ma's annual filings.
Vertex Pharmaceuticals Inc / Ma (VRTX) breaks its revenue down by revenue line and region. In fiscal 2025, its largest revenue line was Trikafta/Kaftrio, with $10.31B or 85.2% of the total, followed by Alyftrek at $837.80M (6.9%).
Trikafta/Kaftrio was Vertex Pharmaceuticals Inc / Ma's largest revenue line in fiscal 2025, with $10.31B in revenue, 85.2% of the $12.10B reported across its 7 revenue lines.
United States was Vertex Pharmaceuticals Inc / Ma's largest region in fiscal 2025, with $7.55B in revenue, 62.9% of the $12.00B reported across its 3 regions.
Of the Vertex Pharmaceuticals Inc / Ma regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, United States grew the fastest, rising 12.9% from $6.68B to $7.55B.
Every figure is taken from Vertex Pharmaceuticals Inc / Ma's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2013 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.